Eli Lilly lifts 2026 revenue outlook to $91‑$92 billion after 39% Q3 growth
Eli Lilly reported third‑quarter revenue of $24.4 billion, up 39% year over year, and announced it raised its 2026 sales guidance to a range of $91 billion‑$92 billion, up $5.5 billion from the prior midpoint. The company said the increase reflects strong demand, although about $2 billion of the quarter’s revenue came from one‑time milestone and rebate benefits that will not recur. Volume grew 53% while realized prices fell 15%, and gross margin edged higher to 83.9%.
Why it matters
The higher guidance signals a larger revenue base for the coming year, but the company cautions that one‑time benefits will disappear, meaning future growth must come from volume and pricing trends. Investors will watch whether the company can sustain mid‑teens organic growth once the $2 billion of non‑recurring revenue is removed.
Key facts
- 1Third‑quarter revenue was $24.4 billion, a 39% increase year over year. finance.yahoo.com
- 2The company raised its 2026 revenue guidance to $91 billion‑$92 billion. finance.yahoo.com
- 3The guidance midpoint rose $5.5 billion, or about 6.4%, from the previous midpoint. finance.yahoo.com
- 4Volume grew 53% in the quarter. tikr.com
- 5Realized prices fell 15% in the quarter. tikr.com
- 6Gross margin increased to 83.9% in the quarter. tikr.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.